SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) and the Australian Stem Cell Centre (ASCC) announced today that they have signed an agreement whereby Chemicon International, Inc., Serologicals' wholly-owned subsidiary, has obtained exclusive rights to commercialize, market and distribute stem cell reagents developed at the ASCC to scientists all over the world. Initial products which will be available to researchers through Chemicon include a novel and proprietary stem cell isolation kit, various proteins, and antibodies. The ASCC is assisting Chemicon in new product development in the research reagent area and expects that other life science tools will also become part of this exclusive research collaboration as they become ready to market. Chemicon will have the first right of evaluation to commercialize these new research reagents developed by the ASCC. In exchange, Chemicon will make an in-kind contribution of research tools for use by researchers in the ASCC laboratories as well as contribute funds, products and technical expertise to the new stem cell training program recently launched by the ASCC. "Chemicon is excited to partner with ASCC to bring a vast array of novel stem cell products and technologies to the market," said Jeffrey D. Linton, President of Chemicon and Upstate, which comprise Serologicals' Research Segment. "This unique arrangement will benefit stem cell research worldwide by enabling access to the many innovative tools developed at the ASCC which will further accelerate research in this exciting area." "The Centre has and will continue to develop high-quality research tools through its research programs, which we believe should be available to all scientists to support the development of the entire stem cell industry. Chemicon is an ideal partner given its extensive stem cell product portfolio, expertise in international distribution and marketing, and dedication to the realization of the potential of stem cell research. "In addition to distributing the ASCC's research reagents, Chemicon is committed to providing novel reagents to our scientists, supporting our training programs, and, most importantly, advancing world-class stem cell research," said Dr Hugh Niall, Chief Executive Officer of the Australian Stem Cell Centre. Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA. For more information, please visit our website: www.chemicon.com Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs approximately 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com. The Australian Stem Cell Centre is Australia's Biotechnology Centre of Excellence. The Centre has partnered with nine leading Australian universities and research institutions and brings together a critical mass of outstanding Australian stem cell research that is internationally competitive and recognised. The Centre's principal objective is to integrate a national multi-institutional research and discovery program to develop treatments for serious disease through the application of stem cells and related technologies. The Australian Stem Cell Centre is funded by the Australian and Victorian Governments. For information regarding access to cell lines or product www.stemcellcentre.edu.au. This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release. Serologicals is a registered trademark of Serologicals Royalty Company.